Načítá se...
Epigallocatechin Gallate in Progressive MS: A Randomized, Placebo-Controlled Trial
OBJECTIVE: To examine whether treatment with epigallocatechin gallate (EGCG) influences progression of brain atrophy, reduces clinical and further radiologic disease activity markers, and is safe in patients with progressive multiple sclerosis (PMS). METHODS: We enrolled 61 patients with primary or...
Uloženo v:
| Vydáno v: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Lippincott Williams & Wilkins
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7954462/ https://ncbi.nlm.nih.gov/pubmed/33622766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000964 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|